147 related articles for article (PubMed ID: 10225470)
1. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
[TBL] [Abstract][Full Text] [Related]
2. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
Haruki S; Minami Y; Suzuki A; Hagiwara N
Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
[TBL] [Abstract][Full Text] [Related]
3. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Kajimoto K; Imai T; Minami Y; Kasanuki H
Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
[TBL] [Abstract][Full Text] [Related]
5. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
[TBL] [Abstract][Full Text] [Related]
6. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
Pollick C
Am J Cardiol; 1988 Dec; 62(17):1252-5. PubMed ID: 3057852
[TBL] [Abstract][Full Text] [Related]
7. An equation to predict the changes in peak left ventricular pressure in hypertrophic obstructive cardiomyopathy after treatment: application to the administration of disopyramide.
Niki K; Sugawara M; Tanino S; Iwade K; Hosoda S; Kasanuki H
Heart Vessels; 1999; 14(2):72-81. PubMed ID: 10651183
[TBL] [Abstract][Full Text] [Related]
8. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
[TBL] [Abstract][Full Text] [Related]
9. [Doppler and echocardiographic assessments of effects of disopyramide on non-obstructive hypertrophic cardiomyopathy].
Nagashima J
J Cardiol; 1991; 21(1):75-86. PubMed ID: 1817183
[TBL] [Abstract][Full Text] [Related]
10. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy.
Teraguchi M; Ikemoto Y; Kobayashi Y
Circ J; 2002 Jul; 66(7):709-11. PubMed ID: 12135145
[TBL] [Abstract][Full Text] [Related]
11. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
Hamada M; Shigematsu Y; Ikeda S; Hara Y; Okayama H; Kodama K; Ochi T; Hiwada K
Circulation; 1997 Sep; 96(5):1520-4. PubMed ID: 9315541
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
Hamada M; Aono J; Ikeda S; Watanabe K; Inaba S; Suzuki J; Ohtsuka T; Shigematsu Y
Circ J; 2007 Oct; 71(10):1540-4. PubMed ID: 17895548
[TBL] [Abstract][Full Text] [Related]
14. Influence of propranolol infusion on cyclic variation of myocardial integrated backscatter in hypertrophic obstructive cardiomyopathy.
Ito T; Suwa M; Kobashi A; Nakamura T; Miyazaki S; Imai M; Kitaura Y
J Am Soc Echocardiogr; 2002 Oct; 15(10 Pt 2):1251-5. PubMed ID: 12411913
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Hamada M; Shigematsu Y; Inaba S; Aono J; Ikeda S; Watanabe K; Ogimoto A; Ohtsuka T; Hara Y; Higaki J
Circ J; 2005 Aug; 69(8):940-5. PubMed ID: 16041163
[TBL] [Abstract][Full Text] [Related]
16. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
Kimball BP; Bui S; Wigle ED
Am Heart J; 1993 Jun; 125(6):1691-7. PubMed ID: 8498312
[TBL] [Abstract][Full Text] [Related]
17. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
[TBL] [Abstract][Full Text] [Related]
18. Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy.
Hartmann A; Kühn J; Hopf R; Klepzig H; Standke R; Kober G; Maul FD; Hör G; Kaltenbach M
Cardiology; 1992; 80(2):81-8. PubMed ID: 1611637
[TBL] [Abstract][Full Text] [Related]
19. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
Sirak TE; Sherrid MV
Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
[TBL] [Abstract][Full Text] [Related]
20. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration.
Pollick C; Kimball B; Henderson M; Wigle ED
Am J Cardiol; 1988 Dec; 62(17):1248-51. PubMed ID: 3195486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
